We are live on ! Find out more
AI

Allostery Investments Portfolio holdings

AUM $7.85M
This Fund
S&P 500
This Quarter Est. Return
+35.03%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.85M
AUM Growth
-$61.5M
Cap. Flow
-$62.1M
Cap. Flow %
-791.46%
Top 10 Hldgs %
82.66%
Holding
46
New
5
Increased
1
Reduced
14
Closed
26

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$443K
2
FULC icon
Fulcrum Therapeutics
FULC
+$216K
3
AKRO
Akero Therapeutics
AKRO
+$204K
4
TRML
Tourmaline Bio
TRML
+$152K
5
TNGX icon
Tango Therapeutics
TNGX
+$98.9K

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$6.08M
2
MRUS
Merus
MRUS
+$5.44M
3
KALV
KalVista Pharmaceuticals
KALV
+$5.11M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$4.18M
5
APGE icon
Apogee Therapeutics
APGE
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2

Similar funds

CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Allostery Investments's Q2 2025 Portfolio in Review

As of Q2 2025, Allostery Investments held 46 positions worth $7.85M, down 89% from $69.3M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Allostery Investments withdrew a net $62.1M in Q2 2025, closing 26 positions and reducing 14 holdings. Its most notable exit was Alkermes, an estimated $3.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Allostery Investments opened a new position in Rezolute worth $532K.

  • Allostery Investments's largest Q2 2025 buy was Rezolute: 119,294 shares worth $532K.
  • Allostery Investments added most to Akero Therapeutics in Q2 2025, an estimated $204K increase.
  • Allostery Investments's biggest Q2 2025 reduction was Abivax, cutting an estimated $6.08M.
  • Allostery Investments fully exited Alkermes in Q2 2025, selling an estimated $3.8M.
  • Allostery Investments's ten largest holdings make up 83% of its $7.85M portfolio in Q2 2025.
  • Allostery Investments opened 5 new positions and closed 26 in Q2 2025.
  • Allostery Investments's portfolio value fell 89% quarter-over-quarter to $7.85M.

Based on Allostery Investments's 13F filing for Q2 2025, filed 14 Aug 2025.